DelveInsight’s “Systemic Sclerosis Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Systemic Sclerosis Market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
The Systemic Sclerosis market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Systemic Sclerosis: An Overview
Systemic Sclerosis (SSc) is an autoimmune disease affecting the connective tissue which in-turn damages the skin and internal organs. It is characterized by a distinctive pathogenic triad of microvascular damage, deregulation of innate and adaptive immunity, and generalized fibrosis in multiple organs.
SSc is a complex and heterogeneous disease, and is, therefore, associated with a wide range of possible signs and symptoms. While the episodes of Raynaud phenomenon can occur weeks to years before fibrosis, a spectrum of digital vascular disease is also observed in SSc.
The US National Library of Medicine states that women are four times more likely to develop this condition as compared to men.
Systemic Sclerosis Market Key Facts
Based on one study conducted by Michele D’Alto et al., patients were divided into 2 subsets (diffuse or limited cutaneous, dc-and lc-SSc) according to the classification of LeRoy et al. Diffuse SSc is found in 15% patients, while limited SSc constitutes of about 85% patients.
As per the NORD (2018), systemic scleroderma is thought to affect 40,000–165,000 people in the US. It may occur at any age, but the symptoms most frequently begin during midlife.
As per the study by Schwartz et al. (2018), Systemic Sclerosis is a rare disease and is diagnosed in approximately 67 male patients and 265 female patients, per 100,000 people each year in the United States.
Systemic Sclerosis Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Systemic Sclerosis market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Systemic Sclerosis market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MoA), Route of Administration (RoA), molecule types, competition with other therapies, brand value, and their impact on the market.
Systemic Sclerosis Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and and views of key opinion leaders.
Systemic Sclerosis Epidemiology Segmentation –
Prevalent Cases of Systemic Sclerosis (SSc)
Prevalent cases of SSc based on Clinical Manifestations
Type-specific Cases of Systemic Sclerosis (SSc)
Age-specific Cases of Systemic Sclerosis (SSc)
Systemic Sclerosis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Systemic Sclerosis market or expected to get launched during the study period. The analysis covers Systemic Sclerosis market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Systemic Sclerosis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Latest Developments in the Systemic Sclerosis Therapeutics Market
On October 07, 2022, Emerald Health Pharmaceuticals Inc. announced that it has completed enrolling the first two cohorts of nine patients in each of its Phase II clinical studies for the lead product candidate, EHP-101. This study evaluates the effectiveness of EHP-101 in treating patients suffering from systemic sclerosis.
On September 13, 2022, aTyr Pharma, Inc. announced that the US FDA had granted the Fast Track Designation for its lead therapeutic candidate, efzofitimod, for the treatment of systemic sclerosis-associated, interstitial lung disease (ILD).
Learn how ongoing clinical & commercial activities will impact the Systemic Sclerosis Market in the coming years:
https://www.delveinsight.com/sample-request/systemic-sclerosis-market
Systemic Sclerosis Therapeutics Analysis
There are a number of treatments that can be effective in Systemic Sclerosis; however, they have many limitations. Most of the therapies have some adverse effects, and there is no single accepted medical treatment for aggressive fibromatosis. Thus, there is a high urgent demand for novel therapies that can overcome the limitations of existing therapies.
To fulfill the unmet need, some of the prominent pharma players at the global level are diligently involved in developing therapies for the treatment of Systemic Sclerosis (SSc).
Some of the key companies in the Systemic Sclerosis Therapeutics Market include:
Forbius
Novartis
Genentech
Galapagos NV
GNI Group
CSL Behring
Seattle Genetics
Kyowa Hakko Kirin
GlaxoSmithKline
Corbus Pharmaceuticals
Kaken Pharmaceutical
Fibrocell, Kadmon Corporation
Cumberland Pharmaceuticals
And many others
Systemic Sclerosis Therapies Covered in the report include:
Lenabasum
Pirfenidone
GLPG1690
Brodalumab
GSK2330811
KD025
Vasculan
FCX-013
AVID200
And many more.
Further Emerging Drugs & Key Companies are Covered in the Report. Download the Sample PDF to Learn More:
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Systemic Sclerosis Competitive Intelligence Analysis
4. Systemic Sclerosis Market Overview at a Glance
5. Systemic Sclerosis Disease Background and Overview
6. Systemic Sclerosis Patient Journey
7. Systemic Sclerosis Epidemiology and Patient Population (In US, EU5, and Japan)
8. Systemic Sclerosis Treatment Algorithm, Current Treatment, and Medical Practices
9. Systemic Sclerosis Unmet Needs
10. Key Endpoints of Systemic Sclerosis Treatment
11. Systemic Sclerosis Marketed Products
12. Systemic Sclerosis Emerging Drugs and Latest Therapeutic Advances
13. Systemic Sclerosis Seven Major Market Analysis
14. Attribute Analysis
15. Systemic Sclerosis Market Outlook (In US, EU5, and Japan)
16. Systemic Sclerosis Access and Reimbursement Overview
17. KOL Views on the Systemic Sclerosis Market
18. Systemic Sclerosis Market Drivers
19. Systemic Sclerosis Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF to Explore the Key Offerings of the Report:
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Shruti ThakurEmail: Send EmailPhone: 09650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/
